FMT May Boost Immunotherapy Effectiveness

AUGUST 25, 2025

FDA Approves Papzimeos for Adults With Recurrent Respiratory Papillomatosis

AUGUST 22, 2025

Texas Declares End of State Measles Outbreak

AUGUST 20, 2025

Email This Article

POSTED: SEPTEMBER 9, 2024

Tecovirimat is Safe but Did Not Improve Clade I Mpox Resolution in the DRC

The antiviral drug tecovirimat did not reduce the duration of mpox lesions among children and adults with clade I mpox in the Democratic Republic of the Congo (DRC), based on an initial analysis of data from a randomized, placebo-controlled trial.
A link to this article will be included in this email.

Recipient's Email Address:

Enter email addresses separated by commas if sending to more than one person. (200 characters max)

Your Name:

Your Email Address:

Send me a copy

Personal Message: (Optional)

These email addresses will only be used to send out this message.

Please wait..

Emerging Diseases

SEPTEMBER 9, 2024

Tecovirimat is Safe but Did Not Improve Clade I Mpox Resolution in the DRC

By IDSE News Staff

To read the full story, Log in or Sign up for a Free Account

Check out our new Clinical tab!

We've added an exciting new feature to our website. Click on "Clinical" in the navbar to explore!

The following result is from the NPI Registry Public Search database. You can click on the NPI number to view detailed information and verify its accuracy. If your NPI is not found in this search, you can try searching again using the form below. If you have difficulty finding your NPI number please contact us at web@mcmahonmed.com

First Name

Last Name

Organization/Institution

State

NPI	Name	Organization/ Institution	State	Zip Code	Taxonomy	Credential	Select